Scholarlink

<p>Breast cancer is a common malignant tumor with a high incidence in women and is relatively rare in men. Non-invasive breast cancer and invasive breast cancer have been classified based on the site of occurrence, each with its own subdivisions. In breast cancer, triple-negative breast cancer is a special type that is unresponsive to endocrine therapy, and treatment primarily relies on chemotherapy, with the combination of immunotherapy and targeted therapy potentially improving efficacy. This article first elaborates on the close relationship between cell death modes, such as apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis, with the occurrence and treatment of breast cancer. Ferroptosis, as a novel form of programmed cell death, is primarily characterized by the accumulation of intracellular lipid peroxides, leading to the disruption of cell membrane integrity and subsequent cell death. The occurrence of ferroptosis depends on the dysfunction of various systems mediated by drug administration, including iron metabolism, lipid metabolism, and amino acid metabolism. Therefore, accumulating evidence has focused on reviewing ferroptosis as a novel form of cell death that shows potential effects for the treatment of breast cancer in basic research and clinical trials. Inducing ferroptosis through various methods may offer new therapeutic strategies, particularly for drug-resistant breast cancer cells. In this review, we aimed to summarize the various metabolic pathways and key genes involved in ferroptosis in breast cancer, as well as the advances in natural product-derived-drugs that effectively regulate the development of breast cancer by modulating ferroptosis. Subsequently, we have provided a comprehensive review of the therapeutical drugs used in the treatment of breast cancer by mediating ferroptosis. Currently, the research and application of ferroptosis-associated drugs are still in the early stages, and further exploration of their mechanisms and the development of more effective treatment methods are needed in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting ferroptosis in breast cancer: mechanisms, biological functions, and natural product-related therapeutic strategies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • Juan Chen,
  • Xiaohua Yuan,
  • Tenglong Zhang,
  • Erhao Zhang

摘要

Breast cancer is a common malignant tumor with a high incidence in women and is relatively rare in men. Non-invasive breast cancer and invasive breast cancer have been classified based on the site of occurrence, each with its own subdivisions. In breast cancer, triple-negative breast cancer is a special type that is unresponsive to endocrine therapy, and treatment primarily relies on chemotherapy, with the combination of immunotherapy and targeted therapy potentially improving efficacy. This article first elaborates on the close relationship between cell death modes, such as apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis, with the occurrence and treatment of breast cancer. Ferroptosis, as a novel form of programmed cell death, is primarily characterized by the accumulation of intracellular lipid peroxides, leading to the disruption of cell membrane integrity and subsequent cell death. The occurrence of ferroptosis depends on the dysfunction of various systems mediated by drug administration, including iron metabolism, lipid metabolism, and amino acid metabolism. Therefore, accumulating evidence has focused on reviewing ferroptosis as a novel form of cell death that shows potential effects for the treatment of breast cancer in basic research and clinical trials. Inducing ferroptosis through various methods may offer new therapeutic strategies, particularly for drug-resistant breast cancer cells. In this review, we aimed to summarize the various metabolic pathways and key genes involved in ferroptosis in breast cancer, as well as the advances in natural product-derived-drugs that effectively regulate the development of breast cancer by modulating ferroptosis. Subsequently, we have provided a comprehensive review of the therapeutical drugs used in the treatment of breast cancer by mediating ferroptosis. Currently, the research and application of ferroptosis-associated drugs are still in the early stages, and further exploration of their mechanisms and the development of more effective treatment methods are needed in the future.